Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The deal carries up to $1.53 billion in potential payments plus tiered royalties and represents Simcere’s sixth out-licensing transaction to date.
The agreement adds another high-profile multinational pharmaceutical company to the growing list of global partners licensing innovative drug candidates originating from China’s biotech industry.
Roche Secures Global Rights to SIM0660
Under the agreement announced on September 1, 2026, Simcere Zaiming grants Roche exclusive worldwide rights to develop, manufacture and commercialize SIM0660.
The financial package includes:
- $75 million upfront payment
- Up to $1.455 billion in potential development, regulatory and commercial milestone payments
- Tiered royalties of up to double digits on future net sales
Together, the upfront and milestone payments could reach $1.53 billion, excluding royalties.
The transaction is particularly notable because SIM0660 remains at the preclinical stage, demonstrating the substantial value global pharmaceutical companies are increasingly placing on differentiated early-stage assets emerging from China.
Reuters also reported the transaction, highlighting Roche’s $75 million upfront commitment to secure worldwide rights to the experimental therapy.
What Is SIM0660?
SIM0660 is a CD79a × CD19 × CD3 tri-specific antibody developed using Simcere Zaiming’s proprietary T-cell engager, or TCE, poly-specific antibody technology.
Its architecture is designed to connect T cells with pathogenic B cells through three targets:
CD3 engages T cells and redirects their cytotoxic activity toward targeted cells.
CD19 and CD79a, meanwhile, provide dual targeting of B cells.
According to Simcere, the molecule combines a CD3-engaging arm with binding domains recognizing both CD79a and CD19, with the goal of inducing potent T-cell-mediated cytotoxicity while limiting cytokine release.
This dual-B-cell-target strategy differentiates SIM0660 from conventional bispecific T-cell engagers that recognize only one B-cell antigen.
Why Target Both CD19 and CD79a?
The dual targeting of CD19 and CD79a could potentially broaden the range of B cells recognized by the molecule and reduce dependence on expression of a single B-cell antigen.
That could be particularly relevant following previous B-cell-directed treatments.
Simcere believes SIM0660’s CD79a/CD19 dual-targeting design may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies.
Conceptually, the mechanism can be summarized as:
T cell (CD3) → SIM0660 → B cell (CD19 + CD79a)
By simultaneously recognizing two B-cell-associated antigens, SIM0660 is intended to provide broader B-cell coverage while its CD3 arm recruits cytotoxic T cells to destroy the targeted cells.
The strategy may also potentially reduce vulnerability to antigen heterogeneity or loss of an individual B-cell target, although this will ultimately need to be demonstrated in clinical studies.
Potential Beyond B-Cell Malignancies
Another important aspect of the Roche transaction is that SIM0660 is not being positioned exclusively as an oncology asset.
Simcere says the candidate has therapeutic potential across B-cell-mediated diseases, including B-cell malignancies as well as autoimmune disorders.
The rationale in autoimmune disease is targeted depletion of pathogenic B cells that contribute to abnormal immune activity.
This reflects a broader trend in drug development in which technologies originally developed to eliminate malignant B cells — including T-cell engagers and CAR-T therapies — are increasingly being investigated for severe autoimmune diseases.
For Roche, therefore, SIM0660 potentially provides a platform-like opportunity spanning both hematologic oncology and immunology rather than a single cancer indication.
Roche Takes Over Global Development
Under the agreement, Roche will assume exclusive global responsibility for the development, manufacturing and commercialization of SIM0660.
That is significant for a preclinical Chinese asset because Roche brings extensive global clinical-development and regulatory capabilities that could accelerate SIM0660’s transition from preclinical studies into human trials.
Boris L. Zaïtra, Roche’s Head of Corporate Business Development, said the transaction reflects Roche’s commitment to partnering with innovative companies to advance new therapeutic options, describing SIM0660 as a potential advancement for patients with B-cell-mediated diseases.
Simcere Zaiming Chairman and CEO Renhong Tang similarly said the collaboration is intended to accelerate clinical development of SIM0660.
Simcere’s Second TCE Platform Out-License
SIM0660 is also the second asset from Simcere’s oncology T-cell engager platform to be successfully out-licensed, further validating the company’s multispecific antibody technology.
The earlier program, SIM0500, is a GPRC5D × BCMA × CD3 tri-specific T-cell engager being developed for multiple myeloma.
Simcere previously entered into a global licensing agreement with AbbVie covering SIM0500, another transaction valued at more than $1 billion in potential consideration.
The two transactions demonstrate how Simcere is increasingly using its T-cell engager platform not only to build its internal oncology pipeline but also to establish partnerships with major global pharmaceutical companies.
Sixth Out-License Pushes Simcere’s Potential Deal Value Above $6.1 Billion
The Roche agreement marks Simcere Pharmaceutical Group’s sixth out-licensing transaction.
According to the company’s announcement, the aggregate potential consideration from these transactions has now surpassed $6.1 billion.
Recent deals have involved several major international pharmaceutical companies and biotechnology partners.
For example, Simcere previously licensed the preclinical bispecific antibody SIM0709 to Boehringer Ingelheim in a deal worth up to €1.05 billion, with Boehringer obtaining rights outside Greater China.
The company has also struck transactions involving oncology assets including SIM0500 and antibody-drug conjugates emerging from its pipeline.
The growing cumulative value of these transactions illustrates a broader transformation taking place within Chinese biopharma: companies that historically focused heavily on China’s domestic market are increasingly becoming sources of globally licensed drug innovation.
Why the Roche Deal Matters
The SIM0660 transaction stands out for several reasons.
First is its stage of development. Roche is committing $75 million upfront and potentially another $1.455 billion before SIM0660 has produced human clinical data.
Second is the molecule’s unusual CD79a × CD19 × CD3 tri-specific architecture, which provides Roche with a differentiated approach to B-cell depletion.
Third is its potential breadth. SIM0660 could theoretically be developed across B-cell malignancies and B-cell-driven autoimmune diseases, significantly expanding the potential commercial opportunity if its mechanism translates successfully into the clinic.
Finally, the transaction further demonstrates global pharmaceutical companies’ appetite for innovative molecules emerging from Chinese R&D platforms.
For Simcere, six out-licensing transactions carrying more than $6.1 billion in aggregate potential consideration provide substantial external validation of the company’s discovery capabilities.
What Comes Next
SIM0660 remains a preclinical-stage candidate, so substantial development risk remains.
Neither company has disclosed a timetable for filing an Investigational New Drug application or beginning a first-in-human study, and no human efficacy or safety data are currently available.
Several questions will therefore become important as Roche advances the program: whether dual CD79a/CD19 targeting translates into more comprehensive B-cell depletion, whether the molecule can maintain strong T-cell-mediated cytotoxicity while controlling cytokine release, and whether the strategy offers meaningful advantages over existing CD19-, CD20- and other B-cell-directed therapies.
Nevertheless, Roche’s decision to acquire global rights for as much as $1.53 billion in upfront and milestone payments, plus royalties, represents a significant endorsement of the program at a very early stage.
For Simcere Zaiming, the deal adds another major global pharma partner to its network and further establishes its T-cell engager platform as an important source of internationally licensed oncology and immunology assets.
References
- Simcere Pharmaceutical Group / Simcere Zaiming. “Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development.” September 1, 2026.
https://en.simcere.com/news/detail.aspx?mtt=1610 - Reuters. “Roche signs global licensing pact for Simcere’s experimental blood cancer drug.” September 1, 2026.
https://www.reuters.com/legal/litigation/roche-signs-global-licensing-pact-simceres-experimental-blood-cancer-drug-2026-09-01/ - BioPharm International. “Simcere Zaiming Licenses Tri-Specific Antibody SIM0660 to Roche in Deal Worth Up to $1.53 Billion.” September 1, 2026.
https://www.biopharminternational.com/view/simcere-zaiming-sim0660-roche-license-agreement - PR Newswire / Simcere. “Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development.” September 1, 2026.
https://www.prnewswire.com/news-releases/simcere-zaiming-enters-exclusive-license-agreement-with-roche-for-sim0660-global-development-302866230.html
